Ernesto Chavez (CRD: 4315877) faces a new pending claim on BrokerCheck over an investment made in 2018. The customer alleges $180,000 in damages, and no arbitrator has ruled on the claim.
Soreide Law Group has been contacted by several investors who purchased Celsion Corp., through the brokerage firm of J.D. Nicholas & Associates. Theses investors are considering pursuing individual claims against J.D. Nicholas for potential sales practice violations through FINRA, The Financial Industry Regulatory Authority.
On January 30th, Celsion Corp., symbol “CLSN”, dropped from $7.78 per share to $1.51 in one day. Celsion Corporation, an oncology drug development company, engages in the development and commercialization of targeted chemotherapeutic oncology drugs based on its proprietary heat-activated liposomal technology. The company develops ThermoDox, a liposomal encapsulation of doxorubicin, which is under Phase III clinical trial for primary liver cancer; under phase II clinical trial for colorectal liver metastasis; and under phase II clinical trial for treatment of recurrent chest wall breast cancer. It has a development, product supply, and commercialization agreement with Yakult Honsha Co. for ThermoDox; The company was founded in 1982 and is based in Lawrenceville, New Jersey.
If you bought CLSN from a J.D. Nicholas broker and sustained significant losses contact Soreide Law Group at (888) 760-6552 or visit https://www.securitieslawyer.com.
Ernesto Chavez (CRD: 4315877) faces a new pending claim on BrokerCheck over an investment made in 2018. The customer alleges $180,000 in damages, and no arbitrator has ruled on the claim.
William Tunink (CRD: 2738224) settled a customer claim for $299,000 on August 11, 2026, according to his BrokerCheck report. The customer alleged that he obtained loans from the customer, and that some of the money went into an investment.
Tony Barouti (CRD: 3031995) faces a pending $230,400 customer claim, according to his BrokerCheck report. He says the allegations in it are false. His report also lists SEC administrative and cease-and-desist proceedings from August 2025.
Phone:
Fax: 1-954-760-6553
Email: [email protected]